(Q34170425)

31 July 2017

1 reference

title

Viral hepatitis A, B, and C. (English)

1 reference

31 July 2017

1 reference

1 reference

Regev A

1

1 reference

31 July 2017

Schiff ER

series ordinal

2

1 reference

31 July 2017

publication date

1 February 2000

1 reference

31 July 2017

published in

Clinics in liver disease

1 reference

31 July 2017

volume

4

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

47-71, vi

1 reference

Epidemiology of hepatitis C

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Post-transfusion hepatitis A

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Effects of lamivudine on replication of hepatitis B virus in HIV-infected men.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

A "NEW" ANTIGEN IN LEUKEMIA SERA

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Efficacy of combined interferon and ribavirin for treatment of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Transient emergence of hepatitis B variants in a patient with chronic hepatitis B resistant to lamivudine.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Vaccine-induced escape mutant of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Predictors of patient and graft survival following liver transplantation for hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Immunogenicity of two versus three injections of inactivated hepatitis A vaccine in adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Cytotoxic T cells and viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

An epidemic outbreak of hepatitis A among homosexual men in Stockholm. Hepatitis A, a special hazard for the male homosexual subpopulation in Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Effect of age on the immunogenicity of yeast recombinant hepatitis B vaccines containing surface antigen (S) or PreS2 + S antigens.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Sexual transmission of hepatitis A in homosexual men: incidence and mechanism.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Evidence that the genome of hepatitis A virus consists of single-stranded RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5' non-coding region

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Reinforced regimen of interferon alfa-2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: a multicentre randomised trial. Multicentre GER-CYT-04 Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Hepatitis C and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

A simian strain of hepatitis A virus, AGM-27, functions as an attenuated vaccine for chimpanzees

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Risk for Non-A, Non-B (Type C) Hepatitis through Sexual or Household Contact with Chronic Carriers

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Fulminant viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Transfusion-Associated Hepatitis Not Due to Viral Hepatitis Type A or B

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Relapsing hepatitis A. Review of 14 cases and literature survey

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Prolonged intrahepatic cholestasis secondary to acute hepatitis A.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Characterisation of an epidemic of hepatitis A virus involving intravenous drug abusers--infection by needle sharing?

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Re-treatment of chronic hepatitis C with consensus interferon .

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Serum HBeAg quantitation during antiviral therapy for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Posttransfusion Hepatitis Type A

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Transmission of Human Hepatitis to Marmosets: Further Coded Studies

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Hepatitis in marmosets: induction of disease with coded specimens from a human volunteer study.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Hepatitis C: the clinical spectrum of disease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Intrafamilial transmission of hepatitis C virus in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

A multistate, foodborne outbreak of hepatitis A. National Hepatitis A Investigation Team

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Arthritis, vasculitis, and cryoglobulinemia associated with relapsing hepatitis A virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Chronic hepatitis A with persistent viral replication

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Membranoproliferative glomerulonephritis associated with hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Hepatitis B viral DNA in liver and serum of asymptomatic carriers.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Seroepidemiology of hepatitis A in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

1 reference

7 January 2021

Viral hepatitis in a group of Boston hospitals. 3. Importance of exposure to shellfish in a nonepidemic period

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Hepatitis Virus: Effect of Heat on the Infectivity and Antigenicity of the MS-1 and MS-2 Strains

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Viral hepatitis, type B (MS-2 strain). Studies on active immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Infectious hepatitis: detection of virus during the incubation period and in clinically inapparent infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Infectious hepatitis. Studies on the effect of gamma globulin and on the incidence of inapparent infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

The natural history of infectious hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Role of breast-feeding in transmission of hepatitis C virus to infants of HCV-infected mothers

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Antiviral therapy for hepatitis B and C in Asians

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Epidemiology of hepatitis C and G in sporadic and familial porphyria cutanea tarda.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Safety and immunogenicity of inactivated hepatitis A vaccine in patients with chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Hepatitis A outbreak amongst intravenous amphetamine abusers in Finland

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Vaccines to prevent viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Combination therapy for hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Hepatitis B virus surface antigen and polymerase gene variants: potential virological and clinical significance

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Long-term follow-up of chronic hepatitis B patients treated with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

LONG-TERM FOLLOW-UP IN A RANDOMISED CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE PATIENTS WITH CHRONIC HEPATITIS B INFECTION

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Further evaluation of the safety and protective efficacy of live attenuated hepatitis A vaccine (H2-strain) in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Combination therapy with famciclovir and interferon-alpha for the treatment of chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Quantitation of hepatitis C virus in liver and peripheral blood mononuclear cells from patients with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Predictors of sustained response to alpha interferon therapy in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Association of diabetes mellitus and chronic hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Production of antibody against "Australia antigen" in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Compact organization of the hepatitis B virus genome

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Hepatitis B viral DNA in infected human liver and in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Jaundice following Administration of Human Blood Products

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Response to hepatitis A vaccination in human immunodeficiency virus-infected and -uninfected homosexual men.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Hepatitis B virus contains pre-S gene-encoded domains

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: a comparison between immunocompetent and immunocompromised patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, Franc

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Safety, immunogenicity, and kinetics of the immune response to a single dose of virosome-formulated hepatitis A vaccine in Thais

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Oyster-associated hepatitis. Failure of shellfish certification programs to prevent outbreaks

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Long-incubation post-transfusion hepatitis without serological evidence of exposure to hepatitis-B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Hepatitis A among schoolchildren in a US-Mexico border community

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Epidemiologic Patterns of Wild-Type Hepatitis A Virus Determined by Genetic Variation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Liver transplantation in European patients with the hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Atypical clinical manifestations of hepatitis A

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Hepatitis C and alcohol

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Natural history of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Characterization and classification of virus particles associated with hepatitis A. II. Type and configuration of nucleic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Hepatitis A virus infections associated with clotting factor concentrate in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Chronic hepatitis B: interferon-monotherapy or combination with nucleoside analogues?

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Immunization of seronegative infants with hepatitis A vaccine (HAVRIX; SKB): a comparative study of two dosing schedules

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Fulminant Hepatitis Associated with Hepatitis A Virus Superinfection in Patients with Chronic Hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Early HCV RNA values after interferon predict response

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Impact of alcohol on the histological and clinical progression of hepatitis C infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Twelve-year follow-up of a prospective randomized trial of hepatitis b recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970096-9

7 January 2021

10.1016/S1089-3261(05)70096-9

Identifiers

DOI

1 reference

31 July 2017

1 reference